Bioverge

Kiersten Stead, Co-Founder and Managing Partner of DCVC Bio sits down with Neil to discuss her firm’s approach to deep tech investing in biotech, her focus on platform technologies, and how to separate what’s real from what’s hype in AI

Andrew Lo, Professor of Finance, and the Director of the Laboratory for Financial Engineering at the MIT Sloan School of Management, sits down with Neil to discuss his application of portfolio theory to address the challenges of funding drug development and how a Netflix subscription model can address the coming crisis in funding high-priced curative therapies approaching the market.

Faizzan Ahmad, Co-Founder and CEO of Cure8bio, sits down with Neil to discuss its growing portfolio of regenerative medicines in development, its hub-and-spoke business model designed to leverage resources and reduce risk, and its push toward curative therapies.

Nathan Hunkapiller, Chief Scientific Officer and Co-Founder of Curve Biosciences, sits down with Neil to discuss liquid biopsies, the company’s efforts to expand the use of these blood-based tests to improve the treatment of chronic diseases, and how it is enabling earlier intervention.

Drew Titmarsh, Co-Founder and CEO of Dynomics, sits down with Neil to discuss that lack of innovative therapies to treat heat disease, the company’s discovery platform that uses engineered cardiac organoids that function like adult human heart tissue, and how the company is using this to develop precision therapies to address the root causes of heart failure.

David Li, Co-Founder and CEO of Meliora Therapeutics, sits down with Neil to discuss why the mechanism of action for cancer therapies in development is poorly understood, how this leads to a high and costly clinical failure rate, and how Meliora's platform technology uncovers the true mechanism of action of a drug and it enables it to identify promising drug scaffolds to accelerate the development process.

Anat Burkovitz, CEO of TrojanBio, sits down with Neil to discuss its AI-drive antibodies platform, how it enlists the viral immune system in the fight against cancer, and why she thinks the technology will broaden the population of patients who will benefit from immunotherapies.

Amit Etkin, Founder and CEO of Alto Neuroscience, sits down with Neil to discuss the lack of innovation in psychiatric medicines, how the company has identified AI-derived brain biomarkers, and how that is fueling its pipeline of precision therapies to treat mental health disorders.

Vineeta Agarwala, General Partner at Andreessen Horowitz's Bio + Health Fund, sits down with Neil to discuss their investment process, how technology is transforming biotech and healthcare, and why she thinks drug development is becoming more and more like software development.

David Kirn, Co-Founder and CEO of 4DMT, sits down with Neil to discuss the limits of existing AAV vectors and how his company is using its Therapeutic Vector Evolution platform to invent customized vectors that allows it to take a disease specific approach to unlock the potential of genetic medicines.